Home / Posts Tagged "Cipla"

In a strategic move to expand its footprint in the paediatric and wellness segment, Cipla Limited has announced the acquisition of Inzpera Healthsciences Ltd for ₹110.65 crore.The acquisition underscores Cipla’s continued focus on diversified consumer healthcare solutions, particularly in the areas of child nutrition, gut

READ MORE

n a landmark development for global cancer care, Cipla Limited (BSE: 500087; NSE: CIPLA EQ), a leading global pharmaceutical company, today announced that it has received final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for

READ MORE

Axis Securities Report Highlights Positive Trends for Q2 FY25The Indian pharmaceutical industry is poised for a robust year, with revenue growth projected at 8.5% year-on-year (YoY) for the second quarter of FY25, driven primarily by domestic formulations and strategic niche launches in the US market.

READ MORE

Cipla Ltd. made headlines on Tuesday with a significant update regarding its board of directors. Mustafa Khwaja Hamied, commonly known as MK Hamied, will step down from his role as vice-chairman and non-executive director. The resignation will be effective at the close of business on

READ MORE

 To commemorate National  Organ Donation Day, Bai Jerbai Wadia Hospital for Children honored the families of four young children who chose to donate organs following the heartbreaking declaration of brain death as well as its dedicated staff members. The selfless act provided a vital gift

READ MORE

Experts discuss Regulatory Reforms, Ease of Doing Business during Health & Wellness Week at India PavilionThe India Pavilion at EXPO2020 Dubai yesterday hosted a roundtable, ‘India –Pharmacy  of the world’ as part of the ongoing Health & Wellness week, wherein several government and industry experts

READ MORE

On Monday, the companies said in a joint statement that India's Cipla (CIPL.NS) has signed a deal with Eli Lilly (LLY.N) to sell and distribute two of the U.S. drugmaker's best-selling diabetes treatments in the country. The companies said, Lilly will transfer its rights in India to sell, promote

READ MORE